Published in Am J Hypertens on August 01, 2007
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag (2011) 0.89
Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats. Exp Biol Med (Maywood) (2011) 0.77
Physiology and Pathophysiology of the Intrarenal Renin-Angiotensin System: An Update. J Am Soc Nephrol (2017) 0.77
The effect of aliskiren on the renal dysfunction following unilateral ureteral obstruction in the rat. Int J Physiol Pathophysiol Pharmacol (2016) 0.75
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 2.78
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens (2007) 2.43
Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am J Hypertens (2011) 1.60
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens (2013) 1.57
Pressor responses to antihypertensive drug types. Am J Hypertens (2010) 1.56
The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens (2011) 1.46
Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens (2002) 1.45
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens (2009) 1.28
Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens (2011) 1.27
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens (2006) 0.94
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens (2003) 0.94
Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens (2002) 0.93
Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens (2004) 0.92
Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens (2004) 0.92
Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab (2005) 0.87
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res (2011) 0.86
Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens (2003) 0.85
Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens (2008) 0.80
Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape. Am J Hypertens (2004) 0.77
"Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension (2010) 0.77
Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system. Am J Hypertens (2004) 0.76
Optimal resources for the examination and endovascular treatment of the peripheral and visceral vascular systems. AHA Intercouncil Report on Peripheral and Visceral Angiographic and Interventional Laboratories. J Vasc Interv Radiol (2003) 0.76
Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism. J Hypertens (2005) 0.75
Using plasma renin (PRA) testing to design follow-up drug treatment strategies in hypertensive patients already taking antirenin system drugs. Am J Hypertens (2009) 0.75
Authors' reply to Messerli and colleagues. BMJ (2013) 0.75
Plasma renin activity enzyme-kinetic assay: protection of Angiotensin I from bacterial degradation. Clin Chem (2010) 0.75
It is the plasma renin activity level that counts, not stoichiometry. Hypertension (2008) 0.75
More about plasma renin and cardiovascular mortality. Eur Heart J (2011) 0.75
ACE inhibitors and major congenital malformations. N Engl J Med (2006) 0.75
Dr. Michael H. Alderman takes the helm as editor-in-chief of the American Journal of Hypertension. Am J Hypertens (2006) 0.75
Plagiarism and scientific misconduct. Am J Hypertens (2004) 0.75